T

TXG

TXG

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
0%Bearish
Buy/Sell Ratio0% buys
BearishBullish
TXG Live QuoteReal-time
$57.38
$18.21(-24.09%)1M
Day Range$56.96 – $61.74
Open$59.18
Previous Close$57.07
Volume2.32M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$7.55B
P/E Ratio (TTM)24.5
Forward P/E5000.0
EPS (TTM)$-0.52
Price to Book9.0
Dividend Yield0.65%
Beta (Volatility)2.03
IndustryMEDICAL DEVICES
52-Week RangeCurrent: $57.38 (48%)
Low: $15.18High: $102.81
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$68.14-54.6% upside

Insider Buys

0

$0

Insider Sales

2

$3.98M

Total Volume

$3.98M

2 transactions

Net Activity

$3.98M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
25CONFIDENCE

Sentiment Rating

Moderate Distribution

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Heavy distribution: sales represent 100% of total transaction value.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
S
1

Saxonov Serge

CEO

0 buys2 sells

$3.98M total

Trading History
TXG insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Nov 10, 2026

1 weeks ago

Saxonov Serge

CEO

CEO
Sell31.0K$62.90$1.95M

Sep 22, 2026

1 months ago

Saxonov Serge

CEO

CEO
Sell25.0K$81.22$2.03M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
TXG Buy Conviction0%
Industry Rank#288 of 569
Volume Contribution0.0%
Total Industry Activity$16.52B

TXG has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. TXG ranks #288 in insider activity out of 569 tracked companies in its industry.

Insider Trading Summary & Commentary
Automated executive transaction analysis for TXG

Over the last 90 days, corporate insiders at TXG (TXG) engaged in a total of 2 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 2 were sales. The total volume of insider trading reached $3.98M.

The net insider activity for TXG shows a net selling bias of $3.98M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Saxonov Serge (CEO), who traded 25.0K shares valued at $2.03M on Sep 22, 2026.

Live Market News & Developments
Aggregated real-time headlines for TXG (TXG)
6 updates

10x Genomics, Inc. (TXG) Stock Price, News, Quote & History

Yahoo! Finance Canada6h ago

Will TXG Stock Ever Get Back To Its Old High?

Trefis21d ago

TXG - 10x Genomics Inc Stock Price and Quote

Finviz177d ago

10x Genomics (TXG) Stock May Look Pricey As Oncology AI News Lands

Yahoo Finance62d ago

10x Genomics (NasdaqGS:TXG) Stock Forecast & Analyst Predictions

Simply Wall St10d ago

TXG Stock Rallies As AI Deal And Legal Win Shift Outlook

StocksToTrade57d ago

FAQs About TXG Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for TXG.

Based on SEC Form 4 disclosures, the Insider Confidence Score for TXG is currently 25/100, which reflects a moderate distribution bias. This calculation accounts for a total of 0 purchases and 2 sales by company executives over the last 90 days.

The CEO Conviction Index for TXG is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.